SecBot SecBot
SECBOTREPLAY Home › Report › ZNTL

ZNTL · Zentalis Pharmaceuticals priced a public offering of 23,000,000 shares…

Zentalis Pharmaceuticals, Inc. · 8-K filed Aug 14, 2026 at 16:09 ET

At the news

BEARISHIMPACT 6/10

8-K filed Aug 14, 2026 at 16:09 ET

Zentalis Pharmaceuticals priced a public offering of 23,000,000 shares of common stock at $3.50 per share, with an underwriter option for an additional 3,450,000 shares. The company expects net proceeds of approximately $75.1 million to fund clinical trials, manufacturing, and general corporate purposes. This dilutive offering represents a significant portion of the company's pre-offering market cap of $297M.

  • 23,000,000 shares of common stock offered at $3.50 per share
  • Underwriters have a 30-day option to purchase up to an additional 3,450,000 shares
  • Estimated net proceeds of approximately $75.1 million
  • Closing expected August 17, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access